Lauren P. Silvernail
2014
In 2014, Lauren P. Silvernail earned a total compensation of $1.7M as Chief Financial Officer and Chief Business Officer at Revance Therapeutics.
Compensation breakdown
Non-Equity Incentive Plan | $124,524 |
---|---|
Option Awards | $757,058 |
Salary | $323,440 |
Stock Awards | $451,080 |
Other | $67,461 |
Total | $1,723,563 |
Silvernail received $757.1K in option awards, accounting for 44% of the total pay in 2014.
Silvernail also received $124.5K in non-equity incentive plan, $323.4K in salary, $451.1K in stock awards and $67.5K in other compensation.
Rankings
In 2014, Lauren P. Silvernail's compensation ranked 5,157th out of 13,032 executives tracked by ExecPay. In other words, Silvernail earned more than 60.4% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 5,157 out of 13,032 | 60th |
Division Manufacturing | 1,840 out of 4,966 | 63rd |
Major group Chemicals And Allied Products | 610 out of 1,686 | 64th |
Industry group Drugs | 465 out of 1,365 | 66th |
Industry Pharmaceutical Preparations | 372 out of 1,043 | 64th |
Source: SEC filing on March 18, 2016.
Silvernail's colleagues
We found three more compensation records of executives who worked with Lauren P. Silvernail at Revance Therapeutics in 2014.